Gut bacteria may hold key to better cancer therapy

NCT ID NCT07263620

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study investigates whether the unique bacteria found inside digestive system tumors can help predict how well a patient will respond to neoadjuvant therapy (chemotherapy before surgery). Researchers will analyze tumor samples from 90 adults with pancreatic, gastric, colorectal, or esophageal cancer. The goal is to develop a model that identifies which patients are most likely to benefit from this treatment, potentially improving outcomes and reducing unnecessary side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to a test that helps doctors choose which patients will benefit from neoadjuvant therapy for digestive cancers.

What could go wrong

This is an early exploratory study with only 90 participants, so results may not apply to all patients. The findings are observational and need further validation.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer digestive system cancer digestive system carcinoma esophageal cancer gastric cancer malignant pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Patients with esophageal, pancreatic, gastric, or colorectal cancer who are scheduled to receive neoadjuvant therapy

    RECRUITING

    Tianjin, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••